ZEB1 and neoplasm: Moreover, in bevacizumab and sorafenib resistant tumor cells, the expression of ZEB1 is increased, and tumors show stronger invasion and metastasis ability [39, 44], suggesting that ZEB1 may play an important role in the process of resistance to anti-angiogenesis therapy.